Advertisement

Breast Cancer Research and Treatment

, Volume 144, Issue 2, pp 437–441 | Cite as

Evaluation of the RHINO gene for breast cancer predisposition in Finnish breast cancer families

  • Tuomas HeikkinenEmail author
  • Sofia Khan
  • Elina Huovari
  • Sara Vilske
  • Johanna Schleutker
  • Anne Kallioniemi
  • Carl Blomqvist
  • Kristiina Aittomäki
  • Heli Nevanlinna
Brief Report

Abstract

Hereditary predisposition to breast cancer is largely affected by the mutations in the genes of the DNA repair pathways. Novel genes involved in DNA repair are therefore prospective candidates also for breast cancer susceptibility genes. The RHINO (Rad9, Rad1, Hus1-interacting nuclear orphan) gene plays a central role in DNA damage response and in cell cycle regulation. RHINO interacts with Rad9-Rad1-Hus1 (9-1-1) complex and with ATR activator TopBP1, which recruit it to the site of DNA damage. We analyzed the effects of the germline variation in RHINO on breast cancer risk. We sequenced the coding region of the RHINO gene 466 index cases of Finnish breast cancer families and in 507 population controls. The genotypes of the most likely functional variant were further determined in a large dataset of 2,944 cases and 1,976 controls. We analyzed the common variation of the RHINO locus and determined the haplotypes using five SNPs in 1,531 cases and 1,233 controls. We identified seven variants including four missense variations, a 5′ UTR variant, a silent variant, and a nonsense variant c.250C>T, R84X (rs140887418). All variants were also present in control individuals with frequencies close to those of the cases (P > 0.05). The c.250C>T variant was present in 12 breast cancer patients (0.4 %) and of 16 controls (0.8 %) with the difference not statistically significant (OR = 0.50, 95 %CI: 0.24–1.06, P = 0.066). The haplotype frequencies did not differ in cases and controls (P = 0.59). Germline variation in the RHINO gene is unlikely to influence inherited susceptibility to breast cancer.

Keywords

RHINO Rad9, Rad1, Hus1-interacting nuclear orphan Breast cancer susceptibility gene Candidate gene Germline variation Genetic risk Familial breast cancer 

Notes

Acknowledgments

We thank research nurse Irja Erkkilä for assistance with data management. The Finnish Cancer Registry is acknowledged for diagnostic data. The study has been funded by the Helsinki University Central Hospital Research Fund, the Sigrid Juselius Foundation, the Finnish Cancer Society, and the Academy of Finland (132473), and for T.H. by the Finnish Cultural Foundation, Orion Farmos Research Fund, and Biomedicum Helsinki Foundation.

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Mavaddat N, Antoniou AC, Easton DF et al (2010) Genetic susceptibility to breast cancer. Mol Oncol 4:174–191PubMedCrossRefGoogle Scholar
  2. 2.
    Shuen AY, Foulkes WD (2011) Inherited mutations in breast cancer genes–risk and response. J Mammary Gland Biol Neoplasia 16:3–15PubMedCrossRefGoogle Scholar
  3. 3.
    Foulkes WD (2008) Inherited susceptibility to common cancers. N Engl J Med 359:2143–2153PubMedCrossRefGoogle Scholar
  4. 4.
    Cotta-Ramusino C, McDonald ER 3rd, Hurov K et al (2011) A DNA damage response screen identifies RHINO, a 9-1-1 and TopBP1 interacting protein required for ATR signaling. Science 332:1313–1317PubMedCrossRefGoogle Scholar
  5. 5.
    Kim JW, Fukukawa C, Ueda K et al (2010) Involvement of C12orf32 overexpression in breast carcinogenesis. Int J Oncol 37:861–867PubMedGoogle Scholar
  6. 6.
    Syrjakoski K, Vahteristo P, Eerola H et al (2000) Population-based study of BRCA1 and BRCA2 mutations in 1035 unselected Finnish breast cancer patients. J Natl Cancer Inst 92:1529–1531PubMedCrossRefGoogle Scholar
  7. 7.
    Kilpivaara O, Bartkova J, Eerola H et al (2005) Correlation of CHEK2 protein expression and c.1100delC mutation status with tumor characteristics among unselected breast cancer patients. Int J Cancer 113:575–580PubMedCrossRefGoogle Scholar
  8. 8.
    Fagerholm R, Hofstetter B, Tommiska J et al (2008) NAD(P)H:quinoneoxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer. Nat Genet 40:844–853. doi: 10.1038/ng.155 PubMedCrossRefGoogle Scholar
  9. 9.
    Vehmanen P, Friedman LS, Eerola H et al (1997) A low proportion of BRCA2 mutations in Finnish breast cancer families. Am J Hum Genet 60:1050–1058PubMedCentralPubMedGoogle Scholar
  10. 10.
    Michailidou K, Hall P, Gonzalez-Neira A et al (2013) Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet 45:353–361PubMedCrossRefGoogle Scholar
  11. 11.
    Heikkinen K, Mansikka V, Karppinen SM et al (2005) Mutation analysis of the ATR gene in breast and ovarian cancer families. Breast Cancer Res 7:R495–R501PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Durocher F, Labrie Y, Soucy P et al (2006) Mutation analysis and characterization of ATR sequence variants in breast cancer cases from high-risk French Canadian breast/ovarian cancer families. BMC Cancer 6:230PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Karppinen SM, Erkko H, Reini K et al (2006) Identification of a common polymorphism in the TopBP1 gene associated with hereditary susceptibility to breast and ovarian cancer. Eur J Cancer 42:2647–2652PubMedCrossRefGoogle Scholar
  14. 14.
    Blaut MA, Bogdanova NV, Bremer M et al (2010) TOPBP1 missense variant Arg309Cys and breast cancer in a German hospital-based case-control study. J Negat Results Biomed 9:9PubMedCentralPubMedCrossRefGoogle Scholar
  15. 15.
    Fletcher O, Houlston RS (2010) Architecture of inherited susceptibility to common cancer. Nat Rev Cancer 10:353–361PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Tuomas Heikkinen
    • 1
    Email author
  • Sofia Khan
    • 1
  • Elina Huovari
    • 1
  • Sara Vilske
    • 1
  • Johanna Schleutker
    • 2
    • 3
  • Anne Kallioniemi
    • 2
  • Carl Blomqvist
    • 4
  • Kristiina Aittomäki
    • 5
  • Heli Nevanlinna
    • 1
  1. 1.Department of Obstetrics and GynecologyUniversity of Helsinki and Helsinki University Central HospitalHelsinkiFinland
  2. 2.Institute of Biomedical Technology/BioMediTechUniversity of Tampere and Fimlab LaboratoriesTampereFinland
  3. 3.Medical Biochemistry and GeneticsInstitute of Biomedicine University of TurkuTurkuFinland
  4. 4.Department of OncologyHelsinki University Central HospitalHelsinkiFinland
  5. 5.Department of Clinical GeneticsHelsinki University Central HospitalHelsinkiFinland

Personalised recommendations